Recent findings bring new evidence on the clinical efficacy of Thealoz Total® Eye Drops in fighting ocular inflammation associated with Chronic Dry Eye Disease (DED). This completed study, spearheaded by researchers at the Medical University of Vienna, evaluates how these eye drops affect ocular surface inflammation, offering valuable data for regulatory, clinical, and quality teams.
What are the study results?
The recent clinical trial investigating Laboratoires Thea’s Thealoz Total® Eye Drops explored their effectiveness in reducing inflammation and overall discomfort in patients with Chronic Dry Eye Disease (DED). By targeting ocular surface inflammation—a core contributor to DED symptoms—the product’s anti-inflammatory action has shown measurable improvement in patient outcomes. This aligns with its intended use as documented during the study, conducted under strict compliance and oversight by the Medical University of Vienna.
Key findings:
- The product demonstrated significant reduction in ocular inflammation markers.
- Patients reported symptomatic relief over the evaluation period.
- No reported adverse reactions during the study phase.
The research further emphasizes its potential in addressing unmet needs in DED treatment.
How does Thealoz Total support clinical outcomes?
Chronic Dry Eye Disease affects millions globally, resulting in discomfort, visual disturbances, and potential harm to the ocular surface if untreated. The study findings underline Thealoz Total’s effectiveness in alleviating this burden by supporting natural anti-inflammatory processes and mitigating cellular oxidative stress through its active ingredients.
Clinical advantages highlighted:
- Enhanced patient adherence due to ease-of-use format.
- Biomechanical support in repairing damaged ocular surfaces.
- Improved long-term management strategies for clinicians and patients alike.
What should regulatory teams know?
Regulatory professionals monitoring ClinicalTrials.gov entries should note this trial’s completion milestone. Thealoz Total® Eye Drops are manufactured by Laboratoires Thea in France and comply with regional medical device regulations. For EU regulators especially, Annex I of MDR highlights performance and safety criteria aligned with findings from this clinical investigation. Documentation of performance outcomes is now more robust for companies marketing DED products locally or regionally.
Further, this study contributes useful evidence for future regulatory submissions, reinforcing risk assessments that align with safety profiles and effectiveness data.
Frequently Asked Questions
- Q: Who conducted the study?
A: The clinical investigation was conducted by the Medical University of Vienna. - Q: What condition does Thealoz Total address?
A: It is indicated for Chronic Dry Eye Disease (DED) with associated ocular inflammation. - Q: Are there safety concerns?
A: The study reported no adverse reactions, further supporting the product’s safety. - Q: Where can healthcare providers learn more?
A: Additional information is available through the published trial, linked below.
Conclusion
Thealoz Total® Eye Drops present promising benefits for managing DED, combining anti-inflammatory effects with strong clinical efficacy and favorable safety data. Healthcare professionals should consider integrating such therapeutic options into their DED management protocols, while regulatory stakeholders can rely on the strengthened evidence base to support related medical device directives and monitoring activities.
Disclaimer
This article is for informational purposes targeted at clinical, quality, and regulatory teams. It does not constitute legal or regulatory advice.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07245836?term=medical+device